Anthropic Launches Beta Voice Mode for Claude AI Chatbot
In the latest AI news development, Anthropic PBC, an American artificial intelligence startup company launched a beta version of voice mode for their AI chatbot Claude.
Company officials announced on their X channel that voice mode is being rolled out in english over the upcoming weeks time. This voice assistant mode will be powered by their latest Claude Sonnet 4 model.
Users can leverage this option in 5 different modes which will vary for paid and free users. Free users will be limited to 20-30 voice messages, while paid subscribers enjoy significantly higher usage limits.
Additionally, only paying users can integrate voice mode with Google Workspace for access to Google apps.
A promo video clip posted by the Company displayed how users can ask Claude via voice mode to access apps like Gmail, Google Docs and Google Calendars to do multiple things. It will also allow users to search the web and switch between text and voice whenever.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
19 minutes ago
- Time of India
India, US discuss metals tariff objection
India is bilaterally discussing with the US its claim at the World Trade Organization (WTO) that there is no basis for New Delhi's proposal to retaliate against the American tariffs on steel and aluminium, said an official. The issue will also be taken up in the India-US bilateral trade agreement (BTA) talks. "The US has said our proposal to retaliate is baseless and we are bilaterally discussing with them at WTO. It's being discussed in the BTA talks also," said the official. In early May, India proposed to levy retaliatory duties on 29 American products including apples, almonds, pears, anti-freezing preparations, boric acid and certain products made of iron and steel under the WTO to counter US tariffs on steel and aluminium. New Delhi told the WTO that these safeguard measures would affect $7.6 billion worth of imports into the US. However, the US refused to discuss the Section 232 tariffs under the Agreement on Safeguards as it does not view the tariffs as a safeguard measure. Section 232 authorises the US president to adjust imports of goods which can threaten to impair US national security. "Given this rejection, India now faces several options including launching a formal WTO dispute under broader GATT rules, challenging the Section 232 tariffs as disguised protectionist actions, arguing that the US is abusing the national security exception," said a Delhi-based trade expert. "This issue will be crucial in the India-US BTA trade talks," said the official. A team of US officials is visiting India this week for discussions on the proposed interim trade agreement between the two countries. The two aim to negotiate the first tranche or phase of a mutually beneficial, multi-sector BTA by fall this year and more than double the bilateral trade to $500 billion by 2030 from the current level of $191 billion. The two sides are likely to agree on an interim trade agreement by the end of June, with New Delhi pushing for full exemption from the 26% reciprocal tariff on domestic goods. On March 8, 2018, the US promulgated safeguard measures on certain steel and aluminium products by imposing 25% and 10% ad valorem tariffs respectively, effective March 23, 2018. On February 10, 2025, it revised the measures on imports of steel and aluminium articles, effective March 12. India said the US failed to notify the WTO Committee on Safeguards on taking a decision to apply safeguard measures, and as an affected member with significant export interest, it has requested consultations with Washington. (The correspondent is in Paris at the invitation of the commerce and industry ministry)
Time of India
25 minutes ago
- Time of India
Elon Musk again accuses Chuck Schumer of corruption, calls him ...
has responded to a Senator Chuck Schumer who has publicly criticised the Tesla CEO , stating that his past actions will cause "lasting damage to the American people." Schumer's comments specifically targeted the Musk's DOGE , asserting that he should apologise to the US citizens. Tired of too many ads? go ad free now "Over and over again, what Musk did with his DOGE is going to cause lasting damage to the American people," Schumer stated in an interview in an interview on "Morning Joe". He dismissed the idea that Musk's current position outside the administration negates responsibility, calling it "ridiculous." "...and just saying, now, he's out of the administration, and he's in a bind. That's, that's ridiculous. He ought to be apologising to the American people for what he has done," he said. Schumer then outlined his expectations, saying, "If for some reason he sees the light. I don't know if he does or not, but that's what we need an apology and him to tell Trump to undo the damage that he has done." Musk calls Chuck Schumer 'Scumbag' In response, the entrepreneur posted on social media platform X, directly addressing Schumer's comments. Replying to a post by a user's post, Musk stated, "@DOGE did 'lasting damage' to his graft and corruption. Chuck Scumbag ." This is not the first time that Musk has called Schumer corrupt. In April, Musk hit at Schumer, accusing him of potentially being involved in government fraud. When Schumer said, 'Trump has unleashed chaos on America', Musk replied, saying, 'Chuck, I'm starting to think you're getting a piece of the action with the government fraud. But no, that couldn't possibly be the reason, could it?…' Schumer was reportedly called 'Scumbag' last year in videos circulating online which showed the an calling him names at the Dominican Day Parade in New York City. "Hey, Chuck. You know Dominicans actually hate your guts, because you're a scumbag. You know that right?" the unidentified man said.
Indian Express
an hour ago
- Indian Express
From no hope to a potential cure for a deadly blood cancer
A group of 97 patients had longstanding multiple myeloma, a common blood cancer that doctors consider incurable, and faced a certain, and extremely painful, death within about a year. They had gone through a series of treatments, each of which controlled their disease for a while. But then it came back, as it always does. They reached the stage where they had no more options and were facing hospice. They all got immunotherapy, in a study that was a last-ditch effort. A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients — a result never before seen in this disease. These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which bought Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as though holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. Dr. June has seen patients who lost six inches in height. 'It's a horrible, horrible death,' Dr. June said. 'Right now advanced myeloma is a death sentence.' (Dr. June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It bought Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge — helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study — they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Taking the Legend CAR-T was difficult — she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache — or an old one — can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' Dr. June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, Dr. June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Dr. Sharpless said. And for those like the patients in the new study who are living at least five years — so far — without disease, the outcome 'really is eye-popping,' Dr. Sharpless said. 'That's getting to a point where you wonder if it will ever come back,' he added. Gina Kolata reports on diseases and treatments, how treatments are discovered and tested, and how they affect people.
